医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Garvan Institute of Medical Research Selects BiOptix Biosensor For Drug Development Research

2015年05月04日 PM07:00
このエントリーをはてなブックマークに追加


 

BOULDER, Colo.

Garvan Institute of Medical Research, one of Australia’s leading biomedical research institutes, announced today they have selected the BiOptix 404pi for their drug discovery research.

BiOptix is a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions. The BiOptix 404pi is used for early-stage drug development, allowing scientists to measure kinetics, affinity constants and concentration. The instrument will be used in the Solvanix labs at the Garvan Institute of Medical Research in Sydney, Australia for stability engineering of human antibody reagents for therapeutic purposes.

“After investigating other SPR instrumentation, we believe that the BiOptix 404pi is the best instrument to aid in our research because of its reliability, high sensitivity and ease of use,” said Daniel Christ, Ph.D., an Associate Professor of Medicine at New South Wales University and Head of the Antibody Therapeutics Lab at the Garvan Institute of Medical Research. “The flexibility of the BiOptix instrument will allow us to use it for a myriad of biomolecular tests, focusing on immunology.”

The Garvan Institute of Medical Research is pioneering study into many of the most widespread diseases including cancer, neurodegenerative and mental diseases, disorders of the immune system, diabetes and obesity, osteoporosis and other skeletal disorders. Solvanix, a company with a technology for improving stability and reducing the aggregation of fully human antibodies, will also utilize the BiOptix 404pi in their research.

“We are pleased to add Garvan to our list of prestigious researchers to adopt the 404pi platform,” said Rick Whitcomb, President and CEO of BiOptix. “This is just the beginning of our relationship with Garvan as we work with them to further their research.”

About BiOptix

BiOptix offers an affordable and powerful solution for drug discovery scientists that require label-free real-time detection of biomolecular interactions. The unique SPR-enhanced instrumentation offers precise measurement of kinetics, affinity constants and concentration, proprietary easy-to-use analytical software, and two operating modes for higher throughput and experimental flexibility.

Based in Boulder, Colorado, BiOptix was founded in 2008 with the mission of making SPR instrumentation more accessible to drug discovery scientists. BiOptix partners with biotechnology, pharmaceutical and academic research organizations to make their drug development process more effective and productive. For more information about BiOptix, visit www.bioptix.com.

About Solvanix

Solvanix is a biotechnology company with a novel technology for improving stability and reducing the aggregation of fully human antibodies. Traditional monoclonal and fragment antibodies can have limited stability and a tendency to aggregate, which greatly impacts manufacturability, formulation and product quality. Solvanix’ proprietary StAbilize™ technology works by boosting stability and reducing aggregation of monoclonal antibodies, antibody fragments and bi-specifics. The Company is working with its biotech and pharma partners to improve their therapeutic antibodies and is providing licenses to the StAbilize™ technology.

For further information please visit: www.solvanix.com

About the Garvan Institute of Medical Research

The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent’s Hospital in Sydney, it is now one of Australia’s largest medical research institutions with over 700 scientists, students and support staff. Garvan’s main research areas are: Cancer, Diabetes & Obesity, Immunology and Inflammation, Osteoporosis and Bone Biology, and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.

For further information please visit: www.garvan.org.au

CONTACT

BiOptix
Jill Thompson, 720-438-8289
jthompson@metzgeralbee.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent